Allogeneic CAR T-cell therapy for relapsed or refractory multiple myeloma: Results from the UNIVERSAL trial

Therapy with B-cell maturation antigen (BCMA)-directed autologous chimeric antigen receptor (CAR) T-cells has demonstrated encouraging efficacy in patients with relapsed/refractory (R/R) multiple myeloma (MM).

Read the full article here

Related Articles